VENTANA PD-L1 (SP142) Assay
Classification
- Category
- Histology & IHC
- Product Type
- Assay Kit
- Technology
- IHC Staining
Application
- Application Area
- Oncology Markers
From the manufacturer
Quoted verbatim from the manufacturer’s published product page. IVDmap did not write or verify this text.
Indication for use Therapy Cutoff Non-Small Cell Lung Cancer (NSCLC) TECENTRIQ ≥ 50% TC or ≥ 10% IC Depending on therapeutic setting, PD-L1 expression in ≥ 50% TC or ≥ 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).
Review and references
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-16
2026-11-02
availability varies